F3 and cancer: The hemostatic system plays a critical role in processes associated with tumor progression such as extracellular matrix degradation, neo-angiogenesis, and distant metastasis.(1) Among the mechanisms associated with the activation of the coagulation system in cancer, two procoagulant factors released by tumor cells have been reported: tissue factor, which initiates the clotting cascade and a cancer procoagulant that activates factor X. Literature supports the fact that the clinical and pathological characteristics of breast cancer correlate well with plasma hemostatic biomarkers.